甲基丁香酚对变应性鼻炎大鼠鼻黏膜组织中黏蛋白5AC的影响

目的：观察甲基丁香酚对变应性鼻炎大鼠鼻黏膜中黏蛋白5AC（MUC5AC）的影响。方法：将72只Wistar大鼠分为正常对照组（12只）和造模组（60只），卵清蛋白致敏Wistar大鼠建立变态性鼻炎动物模型。造模成功后，大鼠随机分为模型对照组、氯雷他定组和甲基丁香酚小、中、大剂量组（10 mg/kg、20 mg/kg、40 mg/kg），各组给药干预，分别在干预1周、2周、4周和6周后取材，采用免疫组织化学检测和实时定量PCR检测MUC5AC mRNA及其蛋白的表达。结果：MUC5AC蛋白阳性表达细胞百分率及MUC5AC mRNA表达量小剂量组在整个干预过程中与模型对照组差异无统计学意义（均P>0.05）；大、中剂量组分别在干预2周和4周后明显减少，差异均有统计学意义（均P<0.05）；氯雷他定组在干预1周后明显减少，差异有统计学意义（P<0.05）。与氯雷他定组MUC5AC蛋白阳性表达细胞百分率比较：中剂量组在干预6周后依然较高（P<0.05），大剂量组在干预6周后差异无统计学意义（P>0.05）。与氯雷他定组MUC5AC mRNA表达量比较，大、中剂量组在干预4周后差异均无统计学意义（均P>0.05）。结论：甲基丁香酚可以显著抑制变应性鼻炎大鼠鼻黏膜中黏蛋白MUC5AC的表达，进而对变应性鼻炎有一定的抑制作用，可为临床应用研究提供依据。
Abstract: Objective: To investigate the effect of methyleugenol on expression of MUC5AC in nasal mucosa of rats with allergic rhinitis (AR). Methods: Seventy-two Wistar rats were randomly divided into 6 groups:normal control group, AR group, loratadine group, low-dose methyleugenol group, middle-dose methyleugenol group and high-dose methyleugenol group with 12 rats in each group. AR was induced by intraperitoneal injection of ovalbumin in latter 5 groups. 10 mg loratadine q.d was given to rats in loratadine group by gavage; and 10 mg/kg, 20 mg/kg and 40 mg/kg methyleugenol were given by gavege q.d to rats in low-, middle-and high-dose methyleugenol groups, respectively. Nasal mucosa samples were obtained from rats at 1, 2, 4 and 6 weeks after drug intervention. The expression of MUC5AC protein and mRNA in nasal mucosa was detected by immunohistochemistry and real-time fluorescence quota PCR (RT-PCR), respectively. Results: Compared with AR, the percentage of cells staining positively for MUC5AC protein and the relative quantity of MUC5AC mRNA in middle-and high-dose methyleugenol groups were significantly decreased after 2 and 4 weeks of drug intervention (P<0.05), but no such decrease was observed in low-dose methyleugenol group at all time points (P>0.05). The percentage of cells with positive expression of MUC5AC protein and mRNA in loratadine group were significantly decreased after 1 week of administration (P<0.05). The percentage of cells with positive MUC5AC protein in middle-dose methyleugenol group was higher than that in loratadine group (P<0.05) after 6 week of drug intervention, but the difference was not seen in high-dose group (P>0.05). There was no significant difference in relative quantities of MUC5AC mRNA after 4 weeks of administration between high-and middle-dose methyeugenol groups and loratadine group (P>0.05). Conclusion: Methyleugenol can attenuate AR through inhibiting the expression of MUC5AC mRNA and protein in